TICKERNERD
Menu
XLOXLOHealthcare · Biotechnology

XLO Stock Forecast: Xilio Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$9.23
0.00% on the day

The 1 Wall Street analysts covering Xilio Therapeutics, Inc. hold a median 12-month price target of $20 — +116.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$60.7M
Ticker Nerd rank
72 / 100
Median analyst target
$20
Analysts covering
1
Total return, dividends reinvested
1W
+0.7%
1M
+6.1%
YTD
+3.0%
1Y
−1.6%
From 52W high
−23.6%
From 52W low
+29.3%
$7
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XLO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xilio Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Revisions
87
Growth
87
Size
81
Quality
78
Momentum
47
Issuance
39
Accruals
20
Value
11

Volatility (98): The share price has been relatively steady.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XLO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XLO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26XLOHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +116.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2025Leerink PartnersInitiatesOutperform$2.00
8 Nov 2024Raymond JamesMaintainsOutperform—
30 May 2023Chardan CapitalReiteratesBuy—
11 May 2023Chardan CapitalReiteratesBuy—
27 Jan 2023Morgan StanleyMaintainsOverweight—
21 Dec 2022Chardan CapitalInitiatesBuy—
10 Nov 2022Raymond JamesMaintainsOutperform—
10 Aug 2022Morgan StanleyMaintainsOverweight—
10 Jan 2022HC Wainwright & Co.InitiatesBuy—
16 Nov 2021Cowen & Co.InitiatesOutperform—
16 Nov 2021Morgan StanleyInitiatesOverweight—
16 Nov 2021Raymond JamesInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XLO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

XLO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Xilio Therapeutics, Inc. (XLO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 86% of US stocks

Price / sales
0.9×

Cheaper than 71% of US stocks

Price / book
1.2×

Cheaper than 68% of US stocks

EV / EBITDA
2.3×

Cheaper than 56% of US stocks

Growth & margins
Revenue growth (YoY)
131.2%

Higher than 95% of US stocks

Earnings growth (YoY)
331.7%

Higher than 93% of US stocks

Gross margin
—
Operating margin
−18.7%

Higher than 22% of US stocks

Net margin
−34.1%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−55.0%

Higher than 20% of US stocks

Return on assets
−13.6%

Higher than 24% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

XLO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XLOXilio Therapeutics, Inc.$60.7M
72
INKTMiNK Therapeutics, Inc.$60.6M
57
INMBINmune Bio, Inc.$61.7M
52
RNXTRenovoRx, Inc.$59.5M
37
BSEMBioStem Technologies, Inc.$63.1M
42
HRTXHeron Therapeutics, Inc.$58.3M
44
IMAImageneBio, Inc.$65.1M
28

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xilio Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XLO news & analysis

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

GlobeNewsWire · 12 Aug 2026positive

Xilio Therapeutics reported its second quarter 2026 financial results and provided pipeline and business updates. The company received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate, and is advancing IND-enabling studies for multi-specific masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND applications anticipated in the second half of 2027. The company said its cash runway into the first quarter of 2028 is expected to support key milestones across its pipeline.

Why it matters — The FDA clearance of the XTX501 IND and progress on its next-generation multi-specific masked immuno-oncology pipeline, supported by a cash runway into early 2028, signal XLO's continued advancement toward key clinical milestones.

FAQ

Frequently asked questions about XLO stock

What is the XLO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Xilio Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XLO stock a buy right now?

Of the 1 analysts covering Xilio Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xilio Therapeutics, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XLO?

As at 22 Aug 2026, Xilio Therapeutics, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will XLO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +116.7% from the last close, and Ticker Nerd's factor model ranks Xilio Therapeutics, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XLO stock forecast for 2030?

No analyst covering Xilio Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XLO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has XLO stock performed over the past year?

Xilio Therapeutics, Inc. returned -1.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xilio Therapeutics, Inc. do?

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies designed to enhance anti-cancer immune responses.

What is the latest news on XLO?

The most recent item we track (GlobeNewsWire, 12 Aug 2026): "Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates". Xilio Therapeutics reported its second quarter 2026 financial results and provided pipeline and business updates. The company received FDA clearance of its IND application for XTX501, a bispecific PD-1/masked IL-2 candidate, and is advancing IND-enabling studies for multi-specific masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND applications anticipated in the second half of 2027. The company said its cash runway into the first quarter of 2028 is expected to support key milestones across its pipeline.

Company

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies designed to enhance anti-cancer immune responses. The company's pipeline includes vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 antibody being evaluated in combination with atezolizumab for advanced solid tumors and microsatellite stable metastatic colorectal cancer, and efarindodekin alfa, a tumor-activated IL-12 molecule in clinical trials for advanced solid tumors. Xilio is also advancing XTX501, a bispecific PD-1/masked IL-2 molecule, and multiple masked T cell engager programs targeting tumor-associated antigens including PSMA, CLDN18.2, and STEAP1. The company's masked immunotherapy platform aims to selectively activate immune responses within the tumor microenvironment while minimizing systemic side effects. Xilio maintains strategic collaborations with major pharmaceutical partners, including an agreement with AbbVie to develop novel tumor-activated antibody-based immunotherapies, and generates collaboration revenue to extend its development runway.

CEO Dr. Rene Russo BCPS, Pharm.D. · 76 employees · United States · https://xiliotx.com